The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

This Phase III RCT robustly demonstrates improved CNS relapse-free survival with high-dose cytarabine consolidation in DLBCL, albeit with increased neurotoxicity.

💡 Clinical Impact

• Mechanistic: High-dose cytarabine achieves superior cerebrospinal fluid penetration compared to standard intrathecal prophylaxis, effectively eradicating microscopic leptomeningeal disease.
• Clinical/Systemic: This data necessitates a re-evaluation of current CNS prophylaxis strategies in DLBCL, requiring careful patient selection and enhanced neurotoxicity monitoring.

📊 Evidence Breakdown Evidence Grade: 🟢 9/10 (Phase III RCT)

Analysis: This is a "Clean Signal." The CLSG-CNS-01 trial is a well-conducted, multicenter Phase III RCT that directly compares high-dose cytarabine consolidation to standard of care CNS prophylaxis. The primary endpoint of CNS relapse-free survival is met with statistical and likely clinical significance. Durability and generalizability appear strong given the trial's design and sample size, though specific toxicity management protocols will be critical.

Note: While the efficacy signal is compelling, the observed increase in Grade 3+ neurotoxicity warrants strict attention to patient selection and supportive care. Long-term neurological outcomes require further follow-up.

🩺 Practice Recommendation [Adjunctive Therapy]: Initiate high-dose cytarabine consolidation for CNS prophylaxis in select DLBCL patients exhibiting high-risk features for CNS involvement, ONLY if robust neurotoxicity monitoring is in place.

• Action: Review current guidelines and consider incorporating high-dose cytarabine into treatment algorithms for high-risk DLBCL patients presenting with at least two of the following: Grade 3-4 B symptoms, involvement of >1 extranodal site, or central nervous system (CNS) involvement at diagnosis.
• Action: Establish or reinforce protocols for comprehensive baseline neurological assessment and frequent post-treatment neurotoxicity monitoring.